Neurocrine Biosciences reported $169.2M in Debt for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Debt Change
Acorda Therapeutics ACOR:US USD 187.69M 2.71M
Agios Pharmaceuticals AGIO:US USD 1.14M 84K
ALKERMES ALKS:US USD 293.9M 633K
Alnylam Pharmaceuticals ALNY:US USD 1.02B 338.25M
Amgen AMGN:US USD 38.94B 241M
Aptinyx Inc APTX:US USD 24.71M 211K
Biogen BIIB:US USD 6.28B 998M
Biomarin Pharmaceutical BMRN:US USD 1.08B 986K
Cytokinetics CYTK:US USD 610.73M 411.31M
Enanta Pharmaceuticals ENTA:US USD 1.42M 83K
Halozyme Therapeutics HALO:US USD 1.5B 258.29M
Intercept Pharmaceuticals ICPT:US USD 332.31M 381.55M
IONIS PHARMACEUT IONS:US USD 1.25B 1.34M
Neurocrine Biosciences NBIX:US USD 169.2M 200K
Regeneron Pharmaceuticals REGN:US USD 2.7B 300K
Repligen RGEN:US USD 284.16M 453K
Rigel Pharmaceuticals RIGL:US USD 39.47M 9.63M
Sarepta Therapeutics SRPT:US USD 1.54B 441.9M
Teva Pharmaceutical TEVA:IT USD 21.27B 816M
Vertex Pharmaceuticals VRTX:US USD 442.3M 40M
YTE INCY:US USD 33.59M 605K